ALGN

Align Technology

Healthcare Medical Instruments & Supplies NASDAQ

About the company

Align Technology, the industry leader in clear aligners, has revolutionized the field of orthodontics since the approval of its flagship product, Invisalign, by the FDA in 1998. With its innovative approach to treating malocclusion, Invisalign quickly gained traction and now dominates the market with a staggering 90% share. One of the key factors contributing to Invisalign's success is its versatility. This remarkable product can effectively address approximately 90% of all malocclusion cases, making it a suitable treatment option for a wide range of patients. To support the growing demand for Invisalign, Align Technology has trained an extensive network of over 230,000 dentists and orthodontists, all specifically trained in the effective use of Invisalign aligners. In recent years, the popularity of Invisalign has reached new heights. In 2022 alone, this remarkable technology treated over 2 million cases, accounting for approximately 10% of all orthodontic cases for the year. Since its inception, Invisalign has transformed the lives of over 14 million patients, giving them the opportunity to achieve their dream smiles without the hassle and discomfort associated with traditional braces. Align Technology's commitment to innovation extends beyond Invisalign. The company also offers a range of cutting-edge intraoral scanners under the brand name iTero. These revolutionary devices capture digital impressions of patients' teeth, enabling clinicians to create detailed and accurate treatment plans. With over 85% of Invisalign cases being submitted using digital scans, the iTero scanners have become an integral part of the treatment process. In fact, iTero scans account for more than half of all the digital scans submitted for Invisalign treatment. The iTero intraoral scanners provide several significant advantages over traditional impression techniques. By eliminating the need for cumbersome physical molds, these scanners deliver improved accuracy and efficiency, streamlining the treatment process for both clinicians and patients. In addition, the digital nature of the scans allows for easy sharing of information with dental laboratories, facilitating effective collaboration between various healthcare professionals involved in the treatment process. Align Technology's commitment to innovation, coupled with the widespread adoption of Invisalign and iTero, has not only transformed the orthodontic industry but has also had a profound impact on countless lives. The popularity of Invisalign continues to grow, as more individuals strive for a discreet and convenient solution to their orthodontic needs. With its unrivaled market dominance and dedication to advancing the field, Align Technology is set to shape the future of orthodontics for years to come.

Website: https://www.aligntech.com

Data updated: June 2, 2026

Sector comparison

We compare this company with the typical (middle) company in the same industry to show how it looks against similar businesses. This is information, not a recommendation.

Healthcare · 1346 peers in sector

Metric ALGN Sector median Vs. industry
P/E 28.58 20.10 ↑ Above average
EPS 5.94 USD -1.14 USD ↑ Above average
Dividend yield 0.00% 0.00%
Profit margin 10.50% 0.00% ↑ Above average
ROE 10.82% -58.84% ↑ Above average

Higher and lower here are only a comparison with the typical company in the industry — a higher or lower value on its own does not mean better or worse.

Financial statements & historical data

Income statements, balance sheets, cash flow, earnings and dividend history are available for registered users

Sign up for free

AI Summary

AI-generated company analysis is available for registered users.

Sign up for free

Where does this data come from?

Frequently Asked Questions

What is Align Technology?
Align Technology, the industry leader in clear aligners, has revolutionized the field of orthodontics since the approval of its flagship product, Invisalign, by the FDA in 1998. With its innovative approach to treating malocclusion, Invisalign quickly gained traction and now dominates the market with a staggering 90% share. One of the key factors contributing to Invisalign's success is its versatility. This remarkable product can effectively address approximately 90% of all malocclusion cases, making it a suitable treatment option for a wide range of patients. To support the growing demand for Invisalign, Align Technology has trained an extensive network of over 230,000 dentists and orthodontists, all specifically trained in the effective use of Invisalign aligners. In recent years, the popularity of Invisalign has reached new heights. In 2022 alone, this remarkable technology treated over 2 million cases, accounting for approximately 10% of all orthodontic cases for the year. Since its inception, Invisalign has transformed the lives of over 14 million patients, giving them the opportunity to achieve their dream smiles without the hassle and discomfort associated with traditional braces. Align Technology's commitment to innovation extends beyond Invisalign. The company also offers a range of cutting-edge intraoral scanners under the brand name iTero. These revolutionary devices capture digital impressions of patients' teeth, enabling clinicians to create detailed and accurate treatment plans. With over 85% of Invisalign cases being submitted using digital scans, the iTero scanners have become an integral part of the treatment process. In fact, iTero scans account for more than half of all the digital scans submitted for Invisalign treatment. The iTero intraoral scanners provide several significant advantages over traditional impression techniques. By eliminating the need for cumbersome physical molds, these scanners deliver improved accuracy and efficiency, streamlining the treatment process for both clinicians and patients. In addition, the digital nature of the scans allows for easy sharing of information with dental laboratories, facilitating effective collaboration between various healthcare professionals involved in the treatment process. Align Technology's commitment to innovation, coupled with the widespread adoption of Invisalign and iTero, has not only transformed the orthodontic industry but has also had a profound impact on countless lives. The popularity of Invisalign continues to grow, as more individuals strive for a discreet and convenient solution to their orthodontic needs. With its unrivaled market dominance and dedication to advancing the field, Align Technology is set to shape the future of orthodontics for years to come.
Are Align Technology shares expensive?
The price-to-earnings (P/E) ratio of Align Technology is 28.58 — the share price is 28.58 times the annual profit per share. That is higher than the typical company in the same industry (industry median: 20.10). This is information, not a recommendation. (as of 2026-06-02)
How big is Align Technology?
The market capitalization of Align Technology — the combined value of all its shares — is 12.16 B USD. The higher the market cap, the larger the company. (as of 2026-06-02)
Does Align Technology pay dividends?
The dividend yield of Align Technology is 0.00% — it shows the annual dividend relative to the share price. This is information, not a recommendation. (as of 2026-06-02)
What sector does Align Technology belong to?
Align Technology operates in the Healthcare sector, industry: Medical Instruments & Supplies.

What do you gain?

With Ecrumen you gain full control over your investments and assets!

All your assets
Stock market investments, real estate, bonds. Be aware of what you have in your portfolio!
AI at the service of your investments
Analyze and optimize your investments using the latest technologies. Sentiments, analyses, tips, reports. Always with up-to-date data!
A community eager to help
Find a place with people similar to you. Share your opinions, see how others manage their investments. Get help with the problems that bother you!
What do you gain?

Want to stay up to date?

Subscribe to our newsletter to stay up to date with Ecrumena news and market information. No spam, unsubscribe in one click.

For more information, please refer to our terms of use.

0/120